Available in Puerto Rico, United States, Brazil
All participants in this study will take either the study medicine (PF-07328948) tablets,
or placebo tablets, once daily, by mouth, every day for 36 weeks. The study determines if
the study medicine (PF-07328948) is safe and effective compared to placebo in people with
heart failure who are already taking standard-of-care medications for heart failure that
include sodium-glucose cotransporter 2 (SGLT2) inhibitors. Participants will be involved
in this study for about 48 weeks. During this time, participants will visit the study
clinic 15 times. In general, 5 of these visits may be performed at home by phone and the
other 10 visits will take place at the study site.
5Research sites
620Patients around the world